Forat G. Lufti, MD

Although data for bispecific antibodies are maturing, CAR T-cell therapy has longer-term data that show prolonged and durable efficacy in LBCL.

Whereas CAR T-cell therapies need weeks to be engineered, bispecific therapies can be ready much quicker for patients with progressing non-Hodgkin lymphoma.

CRS and ICANS may affect patients with lymphoma regardless of whether they receive CAR T or bispecific antibodies, although severity and timing will vary.